Quoin says EMA grants orphan drug designation for QRX003 in peeling skin syndrome
QNRX•Quoin Pharmaceuticals said the EMA granted orphan drug designation to QRX003 for peeling skin syndrome, providing potential benefits including 10-year EU market exclusivity upon approval. The company said its first formal clinical trial for the condition remains on track to start before year-end.
1. Designation and trial timing
Quoin Pharmaceuticals said the EMA granted orphan drug designation to QRX003 for peeling skin syndrome. The status supports protocol guidance, fee reductions and access to EU grants, and provides 10-year EU market exclusivity upon approval; the company said its first formal clinical trial for the condition remains on track to start before year-end.
